Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular outcomes with icosapent ethyl by burden of standard modifiable cardiovascular risk factors in REDUCE-IT.

American journal of preventive cardiology·2026
Same author

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM.

American journal of preventive cardiology·2026
Same author

Distribution of coronary artery calcium volume and density by age, sex, and race using AI-based quantification algorithm.

Journal of cardiovascular computed tomography·2026
Same author

Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT.

European journal of preventive cardiology·2025
Same author

Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease: Chronic Renal Insufficiency Cohort.

JACC. Advances·2025
Same author

Prevalence and Correlates of Lipoprotein(a) Testing in a Diverse Cohort of U.S. Adults.

JACC. Advances·2025

Related Experiment Videos

Initiating statins in the elderly: the evolving challenge.

D Benson Walker1, Terry A Jacobson

  • 1Department of Medicine, Emory University, Atlanta, Georgia 30303, USA.

Current Opinion in Endocrinology, Diabetes, and Obesity
|March 5, 2008
PubMed
Summary
This summary is machine-generated.

Statins effectively reduce cardiovascular risk in elderly patients with existing heart disease. Further research is needed for primary prevention in those over 75, but benefits generally outweigh risks.

Related Experiment Videos

Area of Science:

  • Geriatric Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Underprescribing of statins in elderly patients due to limited evidence in primary prevention, safety concerns, and risk stratification challenges.
  • Existing evidence strongly supports statin use in secondary prevention for the elderly up to age 80.
  • Primary prevention data in individuals over 75 years old remains limited.

Purpose of the Study:

  • To review the evidence for statin use in primary prevention among the elderly.
  • To explore newer risk stratification tools for elderly patients.
  • To assess the safety profile of statins in older populations.

Main Methods:

  • Review of existing clinical trial data and meta-analyses on statin efficacy and safety in the elderly.
  • Evaluation of current and emerging risk assessment tools for cardiovascular disease in older adults.
  • Analysis of factors influencing statin metabolism and dosing in geriatric patients.

Main Results:

  • Statin trials consistently show significant coronary heart disease risk reduction in the elderly for secondary prevention.
  • Limited evidence for statin efficacy in primary prevention in those over 75 years.
  • Meta-analyses suggest overall coronary heart disease and potential cerebrovascular accident risk reduction in the elderly.
  • Lower statin doses may be necessary in the elderly due to drug interactions and altered metabolism.

Conclusions:

  • Statins are beneficial for elderly patients with established coronary heart disease and diabetes mellitus.
  • Further research is required to establish statin efficacy in primary prevention for individuals over 75-80 years.
  • Improved risk assessment tools are needed for optimal statin prescribing in the elderly.
  • The benefits of statin therapy in the elderly generally outweigh the low risk of serious adverse effects.